- Published on
Emergency and Acute Medicine – Lead Poisoning
Basic description
Lead toxicity results from multiple mechanisms. Lead binds sulfhydryl groups, disrupting numerous enzymatic processes, and mimics calcium, interfering with calcium-dependent signaling pathways. High serum lead levels compromise the blood–brain barrier, allowing lead entry into the CNS and causing neurotoxicity. After absorption, up to 99% of lead binds to erythrocytes and is later redistributed into bone, where approximately 95% of total body lead resides in adults and 70% in children. Lead commonly coexists with iron deficiency, which increases gastrointestinal absorption. It also impairs heme synthesis, resulting in elevated free erythrocyte protoporphyrin that complexes with zinc, producing increased zinc protoporphyrin levels. Blood lead levels correlate poorly with symptoms but are associated with reduced IQ and increased behavioral problems.
Etiology
Acute lead toxicity most often results from inhalation of environmental sources or ingestion of lead-containing substances such as pottery glazes, folk remedies, cosmetics, jewelry, weights, home-distilled alcohol, or lead dust from ammunition. Chronic toxicity is usually occupational, particularly in battery manufacturing or recycling, bridge painting, construction, electronic waste recycling, firing ranges, mining, smelting, pottery work, and welding. Pediatric poisoning typically arises from home exposures, including lead-based paint ingestion or inhalation, contaminated water from old pipes, lead dust carried home on clothing, imported foods, and folk medicines.
Diagnosis: signs and symptoms
Neurologic manifestations include seizures, encephalopathy, learning disabilities, psychiatric disturbances, cerebral edema, and peripheral motor neuropathy such as wrist drop, which is classic but uncommon. Gastrointestinal findings include colicky abdominal pain (lead colic), ileus, nausea, vomiting, gingival Burton lines indicating lifetime burden, and occasionally hepatitis or pancreatitis. Cardiovascular effects include hypertension, often secondary to renal disease, as well as myocarditis and conduction abnormalities. Renal involvement presents as chronic renal insufficiency with prolonged exposure. Hematologic effects include anemia from impaired globin synthesis and shortened red blood cell lifespan. Musculoskeletal effects include metaphyseal “lead lines,” reflecting altered calcium deposition rather than lead itself, along with impaired bone growth and strength.
Essential workup
The cornerstone of diagnosis is measurement of a whole blood lead level (BLL). There is no normal BLL. In children, educational and environmental interventions begin at BLL ≥10 μg/dL, while chelation therapy is recommended at ≥45 μg/dL. In adults, chelation is usually considered at ≥70 μg/dL, with levels ≥100 μg/dL associated with severe encephalopathy.
Diagnostic tests and interpretation
Laboratory evaluation includes CBC to assess for anemia, RBC indices and iron studies, renal function tests, electrolytes, glucose, liver function tests prior to chelation, and FEP or ZPP levels. Imaging may include abdominal radiographs to detect radiopaque foreign bodies and long-bone radiographs in children to identify lead lines. Cranial CT and other imaging are guided by clinical status.
Differential diagnosis
Acute presentations may mimic appendicitis, gastroenteritis, colitis, cholera, distributive shock, encephalopathy, or other toxic ingestions. Chronic toxicity may resemble Addison disease, Guillain–Barré syndrome, vitamin deficiencies (B3, B6, B12), or Wernicke–Korsakoff syndrome.
Treatment: prehospital and initial stabilization
Management begins with airway, breathing, and circulation support, cardiac monitoring, and seizure control. Skin decontamination should be performed for dermal exposure when safe. Naloxone, thiamine, and dextrose are administered as indicated for altered mental status.
Emergency department management
Whole-bowel irrigation with polyethylene glycol is indicated if radiopaque material is seen on abdominal imaging; activated charcoal is ineffective. Decisions regarding chelation therapy depend on BLL, symptom severity, acuity of exposure, and consultation with a medical toxicologist or poison center. Adults with encephalopathy or BLL >100 μg/dL typically require chelation with dimercaprol followed by calcium disodium EDTA. Asymptomatic adults with BLL 70–100 μg/dL may be treated with oral succimer, while chelation is not indicated for asymptomatic adults with BLL <70 μg/dL. Children with BLL ≥45 μg/dL require chelation, with DMSA for asymptomatic cases and BAL plus CaNa₂EDTA for symptomatic or very high levels. Pregnant patients require multidisciplinary consultation.
Medications
Chelating agents include dimercaprol (BAL), calcium disodium EDTA, and succimer (DMSA). Supportive medications include benzodiazepines for seizures, dextrose for hypoglycemia, naloxone, and thiamine. BAL is contraindicated in patients with peanut allergy.
Disposition and follow-up
Admission is required for symptomatic patients, children at risk for re-exposure, those unable to tolerate oral chelation, and pregnant patients with elevated BLL. Asymptomatic patients not requiring IV chelation may be discharged once a safe environment is ensured and outpatient follow-up is arranged. Pediatric patients must demonstrate tolerance of oral chelation prior to discharge.
Pearls and pitfalls
Heel-stick testing may falsely elevate BLL and should be confirmed with venous sampling. Environmental assessment and social support are critical to prevent re-exposure. Family members and siblings should be screened when a patient is diagnosed with lead toxicity. Avoid BAL in patients with peanut allergy.
Basic description
Lead toxicity results from multiple mechanisms. Lead binds sulfhydryl groups, disrupting numerous enzymatic processes, and mimics calcium, interfering with calcium-dependent signaling pathways. High serum lead levels compromise the blood–brain barrier, allowing lead entry into the CNS and causing neurotoxicity. After absorption, up to 99% of lead binds to erythrocytes and is later redistributed into bone, where approximately 95% of total body lead resides in adults and 70% in children. Lead commonly coexists with iron deficiency, which increases gastrointestinal absorption. It also impairs heme synthesis, resulting in elevated free erythrocyte protoporphyrin that complexes with zinc, producing increased zinc protoporphyrin levels. Blood lead levels correlate poorly with symptoms but are associated with reduced IQ and increased behavioral problems.
Etiology
Acute lead toxicity most often results from inhalation of environmental sources or ingestion of lead-containing substances such as pottery glazes, folk remedies, cosmetics, jewelry, weights, home-distilled alcohol, or lead dust from ammunition. Chronic toxicity is usually occupational, particularly in battery manufacturing or recycling, bridge painting, construction, electronic waste recycling, firing ranges, mining, smelting, pottery work, and welding. Pediatric poisoning typically arises from home exposures, including lead-based paint ingestion or inhalation, contaminated water from old pipes, lead dust carried home on clothing, imported foods, and folk medicines.
Diagnosis: signs and symptoms
Neurologic manifestations include seizures, encephalopathy, learning disabilities, psychiatric disturbances, cerebral edema, and peripheral motor neuropathy such as wrist drop, which is classic but uncommon. Gastrointestinal findings include colicky abdominal pain (lead colic), ileus, nausea, vomiting, gingival Burton lines indicating lifetime burden, and occasionally hepatitis or pancreatitis. Cardiovascular effects include hypertension, often secondary to renal disease, as well as myocarditis and conduction abnormalities. Renal involvement presents as chronic renal insufficiency with prolonged exposure. Hematologic effects include anemia from impaired globin synthesis and shortened red blood cell lifespan. Musculoskeletal effects include metaphyseal “lead lines,” reflecting altered calcium deposition rather than lead itself, along with impaired bone growth and strength.
Essential workup
The cornerstone of diagnosis is measurement of a whole blood lead level (BLL). There is no normal BLL. In children, educational and environmental interventions begin at BLL ≥10 μg/dL, while chelation therapy is recommended at ≥45 μg/dL. In adults, chelation is usually considered at ≥70 μg/dL, with levels ≥100 μg/dL associated with severe encephalopathy.
Diagnostic tests and interpretation
Laboratory evaluation includes CBC to assess for anemia, RBC indices and iron studies, renal function tests, electrolytes, glucose, liver function tests prior to chelation, and FEP or ZPP levels. Imaging may include abdominal radiographs to detect radiopaque foreign bodies and long-bone radiographs in children to identify lead lines. Cranial CT and other imaging are guided by clinical status.
Differential diagnosis
Acute presentations may mimic appendicitis, gastroenteritis, colitis, cholera, distributive shock, encephalopathy, or other toxic ingestions. Chronic toxicity may resemble Addison disease, Guillain–Barré syndrome, vitamin deficiencies (B3, B6, B12), or Wernicke–Korsakoff syndrome.
Treatment: prehospital and initial stabilization
Management begins with airway, breathing, and circulation support, cardiac monitoring, and seizure control. Skin decontamination should be performed for dermal exposure when safe. Naloxone, thiamine, and dextrose are administered as indicated for altered mental status.
Emergency department management
Whole-bowel irrigation with polyethylene glycol is indicated if radiopaque material is seen on abdominal imaging; activated charcoal is ineffective. Decisions regarding chelation therapy depend on BLL, symptom severity, acuity of exposure, and consultation with a medical toxicologist or poison center. Adults with encephalopathy or BLL >100 μg/dL typically require chelation with dimercaprol followed by calcium disodium EDTA. Asymptomatic adults with BLL 70–100 μg/dL may be treated with oral succimer, while chelation is not indicated for asymptomatic adults with BLL <70 μg/dL. Children with BLL ≥45 μg/dL require chelation, with DMSA for asymptomatic cases and BAL plus CaNa₂EDTA for symptomatic or very high levels. Pregnant patients require multidisciplinary consultation.
Medications
Chelating agents include dimercaprol (BAL), calcium disodium EDTA, and succimer (DMSA). Supportive medications include benzodiazepines for seizures, dextrose for hypoglycemia, naloxone, and thiamine. BAL is contraindicated in patients with peanut allergy.
Disposition and follow-up
Admission is required for symptomatic patients, children at risk for re-exposure, those unable to tolerate oral chelation, and pregnant patients with elevated BLL. Asymptomatic patients not requiring IV chelation may be discharged once a safe environment is ensured and outpatient follow-up is arranged. Pediatric patients must demonstrate tolerance of oral chelation prior to discharge.
Pearls and pitfalls
Heel-stick testing may falsely elevate BLL and should be confirmed with venous sampling. Environmental assessment and social support are critical to prevent re-exposure. Family members and siblings should be screened when a patient is diagnosed with lead toxicity. Avoid BAL in patients with peanut allergy.
0 Comments
